Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2971076 | The Journal of Heart and Lung Transplantation | 2010 | 7 Pages |
Abstract
Valganciclovir prophylaxis among donor-positive/recipient-negative lung transplant recipients delayed but did not eliminate CMV disease or CMV-related deaths and was limited by toxicity and ganciclovir-resistance. Our experience suggests that valganciclovir at reduced-doses or for less than 6 months is sub-optimal in preventing CMV disease.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Dimitra MD, M. Hong MD, Eun J. MD, Fernanda P. MD, MS, Aniket MD, Joseph MD, Maria MD, Yoshiya MD, PhD, Christian MD, Cornelius J. MD,